An Open-label, Multi-centre, Phase Ib Trial to Determine the Dose of Intravenous BI 836826 in Combination With Oral Venetoclax in Chronic Lymphocytic Leukaemia Patients Who Are Eligible for Treatment With Venetoclax
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs BI 836826 (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 08 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Nov 2017 Planned initiation date changed from 1 Dec 2017 to 17 Jan 2018.
- 21 Nov 2017 New trial record